Market | Anhui Liberty Showcased at China Veterinary Drug Conference and Exhibition 2026

On June 18–19, China Veterinary Drug Conference and Exhibition 2026 was held at the Hefei Binhu International Convention and Exhibition Center. Anhui Liberty Pharmaceutical Co., Ltd., a wholly‑owned subsidiary of Leadsynbio, joined the provincial delegation as a representative of outstanding animal health enterprises from Anhui, engaging with industry peers to explore new dynamics in the sector.

During the exhibition, Anhui Liberty highlighted its core products, including Florfenicol and Thiamphenicol, which attracted strong interest from both long‑standing and prospective customers. The company has long been dedicated to the large‑scale production of active pharmaceutical ingredients (APIs) for animal health. It operates a modern manufacturing facility covering 210 mu (approximately 14 hectares) with an annual production capacity of thousand tons. Leveraging the synthetic biology innovation platform of its parent company, Anhui Liberty has developed unique process advantages and green manufacturing capabilities, establishing a solid market position in the Florfenicol segment. In 2024, the company completed a strategic expansion and upgrade of its production lines, achieving automated, intelligent, and standardized closed‑loop manufacturing. A comprehensive quality control system has been put in place, and the company has successfully obtained the latest national GMP certification while passing rigorous audits from numerous domestic and international customers. Its products are now exported to key markets worldwide.

In addition, the company showcased its recently launched L‑Selenomethionine, along with several pipeline carotenoid products including β‑Carotene, Astaxanthin, Canthaxanthin, and Zeaxanthin. Leadsynbio is accelerating its presence in the animal nutrition space, creating synergies with its API business and capitalizing on the Group’s integrated industrial chain to offer customers a diversified portfolio of high‑value‑added solutions.

Looking forward, Leadsynbio will continue to empower its subsidiaries through original innovation, driving the development of new quality productive forces. The company remains committed to further strengthening its full‑industry‑chain capabilities and working alongside industry partners to shape a new chapter of shared growth.